Rita Balice-Gordon
Director/Board Member bei COLLEGIUM PHARMACEUTICAL, INC.
Vermögen: 859 300 $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Rita Balice-Gordon
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 26 | |
Muna Therapeutics ApS
 Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020.
10
| Holding Company | Medical/Nursing Services | 10 |
Capsida Biotherapeutics, Inc.
 Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA.
9
| Holding Company | Miscellaneous Commercial Services | 9 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Rita Balice-Gordon
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
| BIOGEN INC. | Pharmaceuticals: Major | Sales & Marketing Sales & Marketing | |
| DYAX CORP. | Pharmaceuticals: Major | Corporate Officer/Principal President | |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer General Counsel Director of Finance/CFO | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| TIGENIX NV | Medical Specialties | Corporate Officer/Principal | |
| TETRAPHASE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Arthur D. Little, Inc.
 Arthur D. Little, Inc. Miscellaneous Commercial ServicesCommercial Services Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Stanford University | College/University | Undergraduate Degree Undergraduate Degree | |
| Rutgers State University of New Jersey | College/University | Masters Business Admin Undergraduate Degree | |
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA. | College/University | Doctorate Degree Undergraduate Degree | |
| University of Connecticut | College/University | Undergraduate Degree Masters Business Admin | |
| University of Florida | College/University | Graduate Degree Doctorate Degree | |
| University of Massachusetts | College/University | Undergraduate Degree Undergraduate Degree | |
| The State University of New York | College/University | Corporate Officer/Principal Undergraduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree | |
| Vlerick Leuven Gent Management School | College/University | Masters Business Admin | |
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Investment Committee Member | |
| State University of New York at Downstate Medical Center | College/University | Chief Tech/Sci/R&D Officer Doctorate Degree | |
| KARYOPHARM THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
| Methexis Genomics NV | Corporate Officer/Principal | ||
| TiGenix, Inc. | President | ||
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Ovizio Imaging Systems SA
 Ovizio Imaging Systems SA Electronic ComponentsElectronic Technology Ovizio Imaging Systems SA develops and markets imaging systems and sensors. Its microscopes include iLine F, iLine M, iLine S and QMod. The company was founded by Catherine Yourassowsky, Frank Dubois, Philip Mathuis and Serge Jooris in December 2009 and is headquartered in Brussels, Belgium. | Electronic Components | Director/Board Member | |
Inbiomotion SL
 Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Chairman Director/Board Member | |
| Premis BV | Chief Executive Officer | ||
Highlight Therapeutics SL
 Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Pharmaceuticals: Major | Director/Board Member | |
QurAlis Corp.
 QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
NodThera Ltd.
 NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Director/Board Member Chairman | |
Volastra Therapeutics, Inc.
 Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
858 Therapeutics, Inc.
 858 Therapeutics, Inc. BiotechnologyHealth Technology 858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Founder Director/Board Member | |
Montis Biosciences BV
 Montis Biosciences BV BiotechnologyHealth Technology Montis Biosciences BV engages in the development of immune-oncology therapeutics targetting the intersection between vascular dysfunction and immune suppression to treat solid tumors. It offers target screening and assay platform to discover novel targets modulating interactions between tumor endothelial cells and perivascular macrophages. The company was founded by Peter Carmeliet and Massimiliano Mazzone and is headquartered in Meise, Belgium. | Biotechnology | Chairman | |
Jengu Therapeutics, Inc.
 Jengu Therapeutics, Inc. BiotechnologyHealth Technology Jengu Therapeutics, Inc. is a biotechnology company. The company is headquartered in San Diego, CA. | Biotechnology | Director/Board Member | |
Stablix, Inc.
 Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Director/Board Member | |
Mahzi Therapeutics, Inc.
 Mahzi Therapeutics, Inc. BiotechnologyHealth Technology Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Kate Therapeutics, Inc.
 Kate Therapeutics, Inc. BiotechnologyHealth Technology The American company is focused on developing gene therapies to treat muscle and heart diseases using adeno-associated virus (AAV) technology. Kate Therapeutics is applying novel technology platforms to address the limitations of current gene therapies, including tissue-specific delivery and gene regulation. The company's breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies. The company was founded by Eric Wang, Mark Fielden, Alan H. Beggs, Sharif Tabebordbar, Kevin M. Forrest, and Kevin M. Forrest has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Cascador Health BV
 Cascador Health BV Packaged SoftwareTechnology Services Cascador Health BV is a Belgian company that aims to unlock the true value of patient data for better healthcare and better health for individual patients. The company is based in Tielrode, Belgium. The company wants to bridge the gap between data providers and research/industry and become the reference for projects. It was founded in 2021 and the CEO is Philip Taillieu. | Packaged Software | Director/Board Member | |
| Summation Bio, Inc. | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 34 |
| Belgien | 7 |
| Niederlande | 5 |
| Dänemark | 4 |
| Spanien | 4 |
Sektoral
| Health Technology | 30 |
| Consumer Services | 12 |
| Commercial Services | 3 |
| Health Services | 2 |
| Finance | 2 |
Operativ
| Director/Board Member | 187 |
| Corporate Officer/Principal | 69 |
| Independent Dir/Board Member | 65 |
| Chief Executive Officer | 38 |
| Chairman | 37 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| John Freund | 37 |
| Luc Dochez | 26 |
| Gino Santini | 26 |
| Michael Heffernan | 23 |
| John Fallon | 22 |
| Henrijette Richter | 21 |
| Gwen Melincoff | 20 |
| Garen Bohlin | 17 |
| Frank Verwiel | 16 |
| Theodore Schroeder | 16 |
| Isaac E. Ciechanover | 16 |
| Donald Nicholson | 15 |
| Anders Hinsby | 14 |
| Clare Ozawa | 14 |
| Thomas Smith | 13 |
- Börse
- Insiders
- Rita Balice-Gordon
- Unternehmensverbindungen
